Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Idecabtagene Vicleucel Approved for Relapsed or Refractory Multiple Myeloma Free

December 30, 2021

The FDA has approved idecabtagene vicleucel (ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Ide-cel, a personalized immune cell therapy, has been approved as a one-time infusion with a recommended dose range of 300 to 460×106 CAR-positive T cells. This decision is based on data from the phase II KarMMa trial, which enrolled 127 patients with relapsed or refractory MM. Among the efficacy-evaluable population of 100 patients, the overall response rate was 72%, with 28% achieving a stringent complete response (sCR). The median time to response was 30 days (range = 15-88 days) and the median duration of response was 11 months for all patients who responded and 19 months for the 28 patients who achieved an sCR.

"In the KarMMa study, ide-cel elicited rapid responses in the majority of patients, and these deep and durable responses were observed in patients with triple-class exposed and refractory multiple myeloma," said Nikhil C. Munshi, MD, associate director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute.

Serious adverse events (AEs) occurred in 67% of patients, and the most common (occurring in ≥5% of patients) included cytokine release syndrome (CRS), general physical health deterioration, pneumonia, infections, viral infections, sepsis, and febrile neutropenia. The most common grade 3 or higher AEs were febrile neutropenia and infections. Six percent of patients experienced fatal AEs.

This indication carries boxed warnings for CRS, neurologic toxicities, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, and prolonged cytopenia.

Sources: Bristol Myers Squibb news release, March 26, 2021; STAT+, March 26, 2021.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
June 2025

Advertisement intended for health care professionals

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals